Hospitalization Rates Tied to Breast Cancer Chemo Regimen

Share this content:
Hospitalization Rates Tied to Breast Cancer Chemo Regimen
Hospitalization Rates Tied to Breast Cancer Chemo Regimen

(HealthDay News) -- For patients with early-stage breast cancer, hospitalization rates vary with different chemotherapy regimens, according to a study published online in the Journal of Clinical Oncology.

Carlos H. Barcenas, MD, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues compared the risk of hospitalization among patients with early-stage breast cancer.

Data were collected for 3,567 patients older than 65 years from the Surveillance, Epidemiology, and End Results/Texas Cancer Registry-Medicare database and for 9,327 patients younger than age 65 years from the MarketScan database.Patients were classified according to treatment regimens: docetaxel (T) and cyclophosphamide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P.

RELATED: Breast Cancer Resource Center

The researchers found that the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC) among patients younger than 65 years, with significantly higher rates of hospitalization for those who received TAC and AC + T versus TC.

The hospitalization rates ranged from 12.7% (TC) to 24.2% (TAC) among patients older than 65 years, with higher rates of hospitalization for patients who received TAC, AC + T, AC, or AC + weekly P versus TC.

"Results may be affected by selection biases where less aggressive regimens are offered to frailer patients," wrote the authors.

Two authors disclosed financial ties to the medical technology industry.

In an accompanying editorial, Nicole M. Kuderer, MD, of the University of Washington School of Medicine, and Antonio C. Wolff, MD, of the Johns Hopkins Kimmel Center, noted that clinicians have come a long way, but that more research is still needed for better care.

They wrote that "greater funding from government, industry, and private foundations and guidance from policy agencies are needed to enable more quality toxicity research so that we can fully realize the potential of personalized and safe cancer care."


  1. Barcenas CH, Niu J, Zhang N et al. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. J Clin Oncol. 2014;doi:10.1200/JCO.2013.49.3676.
  2. Kuderer N, Wolff AC. Enhancing Therapeutic Decision Making When Options Abound: Toxicities Matter. J Clin Oncol. 2014;doi:10.1200/JCO.2014.55.1903.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs